Fármacos utilizados no tratamento de hipercolesterolemia: uma análise histórica e químico-medicinal

Cedraz, Isaac Santiago; Lavorato, Stefânia Neiva

doi:10.34119/bjhrv3n4-143

Cited by 1 publication

(2 citation statements)

References 48 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…HMG-CoA reductase (3-hydroxy-3-methylglutaryl-coenzyme A reductase or HMGR) is an enzyme of the mevalonate pathway responsible for the synthesis of cholesterol. It is enzyme is a target for numerous drugs, as it participates in the rate-limiting step of endogenous production of cholesterol (Cedraz;Lavorato, 2020;Ram et al, 2021). Among the drugs most used in the treatment of dyslipidemia are statins, which because they have structural similarity to the substrate 3hydroxy-3 methylglutaryl CoA (HMG-CoA), inhibit the enzyme HMG-CoA reductase (EC.…”

Section: Introductionmentioning

confidence: 99%

“…It is enzyme is a target for numerous drugs available on the market to reduce the levels of cholesterol, known as statins that participate in the limiting step of production endogenous cholesterol. The main drugs available on the market are: Simvastatin, Pravastatin, Atorvastatin, Rosuvastatin (Morofuji et al, 2022;Cedraz;Lavorato, 2020;Mouafi;Ibrahim;Elsoud, 2016).…”

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

HMG-CoA reductase inhibitors: an updated review of biosynthesis and patent prospecting

Lins

Oliveira²,

Souza³

et al. 2022

RSD

View full text Add to dashboard Cite

HMG-CoA reductase (3-hydroxy-3-methylglutaryl-coenzyme A reductase) is the enzyme that plays a limiting role in cholesterol biosynthesis. Among the HMG-CoA reductase inhibitor molecules, statins stand out, a class of drug used in the treatment of atherosclerosis and in the reduction of high cholesterol levels, therefore they are biomolecules of medical and pharmaceutical importance. In this context, this work aimed to carry out a systematic mapping of patents and scientific articles related to the biosynthesis of HMG-CoA reductase inhibitors. The search was carried out in the databases of the National Institute of Intellectual Property (INPI), the European Patent Office (Espacenet), the Derwent Innovations Index, the World Intellectual Property Organization (WIPO) and also articles indexed in Scielo and Pubmed using as descriptors “statins”, “production and statins and fungi”, “statins and fungus”. Of the 2561 cataloged patents, 09 were included because they met the inclusion criteria. The number of scientific articles found in the databases was higher (2820) when compared to the number of patents. As a country, China represents the largest holder on the subject, corresponding to 88.9% of patented products. Based on the mapping, advances in the search for strategies for the biotechnological production of statins can be highlighted. Some of the inventions used microorganisms such as filamentous fungi associated with agro-industrial substrates as an alternative and low-cost source for the production of statins to replace synthetic sources. However, future studies can be carried out using new fungi and new renewable substrates, considering the existing biodiversity worldwide.

show abstract

Section: Introductionmentioning

confidence: 99%

Section: Introductionmentioning

confidence: 99%

HMG-CoA reductase inhibitors: an updated review of biosynthesis and patent prospecting

Lins

Oliveira²,

Souza³

et al. 2022

RSD

View full text Add to dashboard Cite

show abstract

Fármacos utilizados no tratamento de hipercolesterolemia: uma análise histórica e químico-medicinal

Abstract: RESUMO Nesse trabalho, são apresentados aspectos relacionados ao desenvolvimento das principais classes farmacológicas utilizadas no tratamento de hipercolesterolemia, explorando-se as características estruturais importantes a sua ação biológica.

Cited by 1 publication

References 48 publications

HMG-CoA reductase inhibitors: an updated review of biosynthesis and patent prospecting

HMG-CoA reductase inhibitors: an updated review of biosynthesis and patent prospecting

Contact Info

Product

Resources

About